News
Read the latest article by our advisor Dr. Joshua Tamayo-Sarver on the current state of CDS tools

A NEW ERA FOR ACUTE CARE

We see what the eye can't. Before it's too late.

Each year, over 700,000 patients die in US hospitals, and 1 in 20 of those deaths are due to late diagnosis and intervention. We help frontline providers recognize acute conditions before they become irreversible, using state-of-the-art AI and routine tests already performed at hospitals.

our innovation engine

Powered by large scale in-silico clinical trials

The confluence of large clinical databases and high-performance artificial intelligence (AI) models is enabling a new paradigm in medical diagnostics.

Biocogniv has built proprietary platforms and datasets that power in-silico clinical trials of unprecedented scale, allowing us to discover new opportunities without incurring the risk and high cost of traditional clinical trials.

1 Billion
LAB RESULTS
1,000+
HOSPITALS

TESTIMONIAL

"Having worked on novel biomarkers for decades, I am genuinely impressed and excited about Biocogniv’s ability to leverage routine blood tests to detect acute conditions before they become obvious. Biocogniv's AI could soon become part of the standard of care in emergency medicine, where we are constantly racing against time."

W. Frank Peacock, MD FACEP FACC

Thought leader in acute care biomarkers
Vice Chair, Emergency Medicine Research
Baylor College of Medicine

TESTIMONIAL

"I oversee innovation at an organization that employs 5,000 frontline providers at hundreds of hospitals, so we've seen many products. I believe Biocogniv's digital biomarkers are a breakthrough in medicine as they go beyond traditional alerts that merely point out what can be known without them – it identifies what is not clinically evident, as early as possible in the patient trajectory."

Joshua Tamayo-Sarver, MD PhD FACEP

Vice President of Innovation, Vituity
Emergency Physician and Biostatistician
Good Samaritan Hospital, CA

TESTIMONIAL

"We have worked on a blinded, independent validation of Biocogniv's digital biomarker, using a large dataset from our 1,000-bed system. The accuracy of the predictions were in excellent agreement with the expected performance of the tool. I think this is going to change how acute conditions are approached by providers."

Peter McCaffrey, MD FCAP

Director, Lab Information Services
Director, Pathology Informatics
University of Texas Medical Branch (UTMB)